Latest Period
Q1 2026
Security Snapshot
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) Institutional Ownership
CUSIP: M96088105
13F Institutional Holders and Ownership History from Q2 2017 to Q1 2026
Institutions Reporting
171
Shares (Excl. Options)
46,421,214
Price
$17.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, par value NIS 0.01 per share
- Symbol
- URGN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 46,421,214
- Total 13F value
- $834,797,714
- Portfolio coverage rank
- 0%
- Share change
- +2,684,270
- Value change
- +$44,202,797
- Number of holders
- 171
- Shares outstanding
- 48,684,257
- SEC-reported price per share
- $29.33
- Insider filing price
- $29.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share is tracked under CUSIP M96088105.
- 171 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 167 to 171 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,023,591,933 to $834,797,714.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 171 institutions filings for Q1 2026.
Security key
M96088105
Latest holder period
Q1 2026
13F holders
171
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
URGN full holder history
UroGen Pharma Ltd. SEC filings
UroGen Pharma Ltd. company facts
UroGen Pharma Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M96088105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
URGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TORONTO DOMINION BANK | 5.4% | +10% | $53,066,960 | +$6,375,626 | 2,616,714 | +14% | The Toronto-Dominion Bank | 31 Mar 2026 |
| BlackRock, Inc. | 5.2% | +4% | $45,305,483 | +$4,235,459 | 2,519,771 | +10% | BlackRock, Inc. | 31 Mar 2026 |
| MORGAN STANLEY | 5.4% | +180% | $35,433,378 | +$24,712,637 | 2,488,299 | +231% | Morgan Stanley | 30 Jun 2025 |
| MENORA MIVTACHIM HOLDINGS LTD. | 5% | $24,780,614 | 2,303,031 | Menora Mivtachim Holdings Ltd | 11 Mar 2025 | |||
| Soleus Capital Master Fund, L.P. | 4.7% | -6% | $31,114,400 | -$1,993,600 | 2,185,000 | -6% | Soleus Capital Master Fund, L.P. | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | -61% | $34,556,086 | -$50,946,098 | 1,703,949 | -60% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| Adage Capital Management, L.P. | 2.8% | -60% | $13,740,520 | -$17,765,685 | 1,277,000 | -56% | Adage Capital Management, L.P. | 31 Mar 2025 |
| Monograph Capital Holdings Advisors, LLC | 1.8% | $8,503,556 | 838,615 | Monograph Capital Partners I, L.P. | 05 Jun 2025 |
As of 31 Mar 2026, 171 institutional investors reported holding 46,421,214 shares of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN). This represents 95% of the company’s total 48,684,257 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 9.3% | 4,543,895 | 0% | 0.81% | $81,699,232 |
| BlackRock, Inc. | 5.8% | 2,845,567 | +9.4% | 0% | $51,163,295 |
| TORONTO DOMINION BANK | 5.4% | 2,616,714 | 0.09% | $47,048,518 | |
| MORGAN STANLEY | 5.3% | 2,560,038 | -0.11% | 0% | $46,029,492 |
| Kynam Capital Management, LP | 4.6% | 2,247,393 | 2.6% | $40,408,126 | |
| Jefferies Financial Group Inc. | 4.5% | 2,199,652 | 0% | 0.48% | $39,549,743 |
| Paradigm Biocapital Advisors LP | 3.5% | 1,703,949 | -62% | 0.63% | $30,637,003 |
| ACORN CAPITAL ADVISORS, LLC | 3.4% | 1,673,420 | +16% | 8.6% | $30,088,092 |
| SG Americas Securities, LLC | 3.4% | 1,657,846 | +20% | 0.03% | $29,808,000 |
| AMERICAN CENTURY COMPANIES INC | 3.4% | 1,637,570 | +21% | 0.02% | $29,443,545 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.1% | 1,503,045 | -14% | 3.2% | $27,024,749 |
| Opaleye Management Inc. | 2.9% | 1,430,000 | +433% | 3.6% | $25,711,400 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 2.7% | 1,314,112 | +68% | 0.24% | $23,627,742 |
| MENORA MIVTACHIM HOLDINGS LTD. | 2.4% | 1,152,531 | 0% | 0.1% | $20,722,507 |
| D. E. Shaw & Co., Inc. | 2.1% | 1,023,159 | +6.3% | 0.01% | $18,396,399 |
| MPM BIOIMPACT LLC | 1.9% | 943,803 | +0.26% | 1.3% | $16,969,578 |
| J. Goldman & Co LP | 1.9% | 938,870 | +83% | 0.78% | $16,880,883 |
| ORBIMED ADVISORS LLC | 1.8% | 875,487 | 0% | 0.36% | $15,741,256 |
| STATE STREET CORP | 1.8% | 874,176 | +8.3% | 0% | $15,717,684 |
| Migdal Insurance & Financial Holdings Ltd. | 1.6% | 770,909 | 0% | 0.12% | $13,860,944 |
| Soleus Capital Management, L.P. | 1.5% | 727,000 | +385% | 0.53% | $13,071,460 |
| GOLDMAN SACHS GROUP INC | 1.2% | 598,528 | +30% | 0% | $10,761,534 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 523,831 | +10% | 0% | $9,418,481 |
| Woodline Partners LP | 1% | 500,726 | 0% | 0.03% | $9,003,053 |
| Boxer Capital Management, LLC | 1% | 500,000 | 0% | 1.2% | $8,990,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
36
Latest
Q1 2026
Rows shown
1-25 of 36
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 46,421,214 | $834,797,714 | +$44,202,797 | $17.98 | 171 |
| 2025 Q4 | 43,711,574 | $1,023,591,933 | +$14,662,063 | $23.42 | 167 |
| 2025 Q3 | 43,904,765 | $877,180,169 | +$94,297,658 | $19.95 | 159 |
| 2025 Q2 | 39,798,464 | $545,161,051 | +$3,475,596 | $13.70 | 149 |
| 2025 Q1 | 41,643,932 | $460,619,197 | +$59,835,372 | $11.06 | 139 |
| 2024 Q4 | 36,306,231 | $386,611,717 | -$9,614,830 | $10.65 | 139 |
| 2024 Q3 | 35,097,143 | $445,735,362 | -$58,506,168 | $12.70 | 127 |
| 2024 Q2 | 38,225,503 | $641,423,803 | +$207,327,873 | $16.78 | 114 |
| 2024 Q1 | 27,162,024 | $407,381,837 | +$84,866,378 | $15.00 | 111 |
| 2023 Q4 | 21,390,291 | $320,854,510 | +$51,912,609 | $15.00 | 103 |
| 2023 Q3 | 17,724,118 | $248,330,352 | +$65,704,038 | $14.01 | 100 |
| 2023 Q2 | 13,209,673 | $136,728,106 | +$7,180,182 | $10.35 | 84 |
| 2023 Q1 | 12,428,895 | $114,822,764 | -$4,446,429 | $9.24 | 64 |
| 2022 Q4 | 13,022,042 | $115,449,037 | -$2,381,858 | $8.87 | 63 |
| 2022 Q3 | 13,319,758 | $110,811,074 | -$981,981 | $8.32 | 56 |
| 2022 Q2 | 13,444,839 | $109,243,080 | -$6,040,297 | $8.19 | 60 |
| 2022 Q1 | 14,223,995 | $123,920,902 | +$1,868,931 | $8.71 | 82 |
| 2021 Q4 | 14,650,914 | $139,360,752 | +$2,176,410 | $9.51 | 71 |
| 2021 Q3 | 14,085,432 | $236,906,894 | +$1,235,828 | $16.82 | 88 |
| 2021 Q2 | 13,993,075 | $213,691,867 | -$5,527,357 | $15.27 | 78 |
| 2021 Q1 | 14,299,652 | $278,497,797 | -$4,203,728 | $19.48 | 88 |
| 2020 Q4 | 14,549,849 | $261,548,580 | -$10,506,654 | $18.02 | 81 |
| 2020 Q3 | 15,009,007 | $288,527,801 | +$6,244,867 | $19.29 | 78 |
| 2020 Q2 | 14,672,947 | $381,998,824 | +$28,263,022 | $26.12 | 83 |
| 2020 Q1 | 13,991,634 | $249,248,555 | -$10,038,151 | $17.84 | 78 |